# Recursion Pharmaceuticals **Source:** https://geo.sig.ai/brands/recursion-pharmaceuticals **Vertical:** Healthcare Tech **Subcategory:** AI Drug Discovery / Computational Biology **Tier:** Challenger **Website:** recursion.com **Last Updated:** 2026-04-14 ## Summary Public AI drug discovery platform (NASDAQ: RXRX). 5 clinical programs. Merged with Exscientia ($688M). 2025 rev $74.7M. $755M cash. Founded 2013, Salt Lake City. ## Company Overview Recursion Pharmaceuticals (NASDAQ: RXRX) is a computational biology company industrializing drug discovery with AI, founded in 2013 in Salt Lake City, Utah. Built Recursion OS, a vertically integrated platform unifying biology, chemistry, and clinical development. Completed $688M all-stock Exscientia merger (November 2024). Market cap ~$1.62B. 2025 revenue $74.7M, net loss $929.8M. Cash: $755M (runway through 2027). Partnerships with Sanofi, Roche, Bayer, and Merck generated $500M+ in payments. In early 2026, Najat Khan became CEO as co-founder Chris Gibson moved to Chairman. Combined pipeline: 5 clinical programs, 15+ discovery programs. Lead asset REC-4881 (MEK1/2 inhibitor for FAP) showed 53% median polyp reduction in Phase 1b/2. Planning FDA engagement for registration pathway in H1 2026. ## Frequently Asked Questions ### What is Recursion Pharmaceuticals? Computational biology company (NASDAQ: RXRX) using AI to industrialize drug discovery via its Recursion OS platform. ### What was the Exscientia merger? $688M all-stock merger (November 2024) creating one of the largest AI drug discovery platforms with end-to-end capabilities. ### What is REC-4881? Lead MEK1/2 inhibitor for Familial Adenomatous Polyposis showing 53% median polyp reduction in Phase 1b/2. FDA engagement planned H1 2026. ### What is Recursion's financial position? 2025 revenue $74.7M, $755M cash (runway through 2027), $500M+ in partnership payments from Sanofi, Roche, Bayer, Merck. ### Who leads Recursion? Najat Khan, Ph.D. (CEO since early 2026). Co-founder Chris Gibson transitioned to Chairman. ### What is the Recursion OS platform? Recursion OS is the company's integrated AI drug discovery platform combining high-throughput biological experimentation (testing millions of compound-disease combinations in cellular assays) with deep learning models trained on the resulting datasets. The platform maps disease biology by measuring how genetic perturbations and compounds affect cell morphology, generating a proprietary 'biological map' that Recursion uses to identify drug candidates and predict their behavior in human biology. ### How did the Exscientia merger change Recursion? The all-stock merger completed in November 2024 combined Recursion's phenomics and biological data platform with Exscientia's AI-driven chemistry and small molecule design capabilities. The combined company gained end-to-end AI drug discovery from target identification through clinical candidate selection, with combined computational chemistry capabilities that neither had independently. The deal was valued at $688 million and created one of the largest AI drug discovery platforms by market presence. ### What is Recursion's relationship with Nvidia? Recursion has a strategic partnership with NVIDIA that includes access to DGX Cloud computing infrastructure for training its BioFoundation models and a collaborative research relationship on AI for biology. NVIDIA participated in Recursion's funding rounds and the partnership reflects NVIDIA's strategy of investing in AI companies that generate demand for GPU compute in the life sciences sector — one of the highest-value applications of large-scale AI. ## Tags b2b, healthtech, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*